This firm currently holds 1.03
M in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest Apyx Medical is not taking enough advantage from borrowing.
We provide trade advice to complement the prevailing
expert consensus on Apyx Medical Corp. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
We determine the current worth of Apyx Medical using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Apyx Medical based exclusively on its
fundamental and basic
technical indicators. By analyzing Apyx Medical's
financials, quarterly and monthly indicators, and related drivers such as
dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of
Apyx Medical's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Apyx Medical. We calculate exposure to Apyx Medical's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Apyx Medical's related companies.
Apyx Medical Investment Alerts
Apyx investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Apyx Medical performance across your portfolios.Please check all
investment alerts for Apyx
Apyx Medical Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare Apyx value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Apyx Medical competition to find
correlations between indicators driving the intrinsic value of Apyx.
Apyx Medical Gross Profit
Apyx Medical Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Apyx Medical previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Apyx Medical Gross Profit growth over the last 10 years. Please check Apyx Medical's
gross profit and other
fundamental indicators for more details.
Details
The current price rise of Apyx Medical Corp could raise concerns from investors as the firm it trading at a share price of
9.66 on
237,082 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in
May. The stock standard deviation of daily returns for 30 days investing horizon is currently 4.76. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Apyx Medical partners.
| 2018 | 2019 | 2020 | 2021 (projected) |
Interest Expense | 104 K | 8 K | 7.2 K | 7.39 K | Gross Profit | 10.83 M | 19.09 M | 21.96 M | 17.62 M |
Margins Breakdown
Apyx Medical profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Apyx Medical itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Apyx Medical profit margins.
| EBITDA Margin | (0.8) |
| Gross Margin | 0.7 |
| Profit Margin | (0.82) |
Apyx Medical Average Assets is increasing over the last 8 years. Also, Apyx Medical Average Equity is fairly stable at the moment.
Analysis of Apyx Medical Corp
Current semi variance is at 12.09.
As of the 31st of March, Apyx Medical shows the Downside Deviation of 3.73,
risk adjusted performance of 0.1168, and Mean Deviation of 3.49. Apyx Medical Corp
technical analysis gives you the methodology to make use of
historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of
historical prices and volume momentum, or the prices will eventually revert. We have analyzed and interpolated nineteen
technical drivers for Apyx Medical Corp, which can be compared to its rivals. Please confirm
Apyx Medical Corp jensen alpha and
semi variance to decide if Apyx Medical Corp is priced correctly, providing market reflects its regular price of 9.66 per share. Given that Apyx Medical has
jensen alpha of 0.5857, we suggest you to validate Apyx Medical Corp's prevailing market performance to make sure the company can sustain itself at a future point.
Our Final Takeaway
While some companies under the medical devices industry are still a bit expensive, Apyx Medical may offer a potential longer-term growth to investors. While some investors may not share our view we believe it may be a good time to exit Apyx Medical as the risk-reward trade off is not appealing enough to hold a position. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Apyx Medical.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Apyx Medical. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
